Comparison of the effects of clozapine and chlorpromazine on auditory sensory gating in patients with schizophrenia: a prospective case-control study

Shanghai Archives of Psychiatry

Volumn 23, Issue 3, 2011, Pages 161-165

  Su, Liang ^a   Shi, Shen Xun ^a   Wang, Ji Jun ^b   Li, Hui ^b   Wang, Li Wei ^a   Zhang, Ming Yuan ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Auditory evoked potentials; Chlorpromazine; Clozapine; P50 sensory gating; Schizophrenia

Indexed keywords

EID: 84860799050     PISSN: 10020829     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1002-0829.2011.03.005     Document Type: Article

References (20)

1. De Wilde O M, Bour L J, Dingemans P M, Koelman J H, Linszen D H. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res, 2007, 97(1-3): 137-151.
2. Hong X, Chan R C, Zhuang X, Jiang T, Wan X, Wang J, et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res, 2009, 108(1-3): 151-157.
3. 2006, 39(4): 193-196.
4. 2006, 39(2): 65-68.
5. 2007, 40(4): 230-233.
6. Patterson J V, Hetrick W P, Boutros N N, Jin Y, Sandman C, Stern H, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res, 2008, 158(2): 226-247.
7. Adier L E, Olincy A, Cawthra E M, McRae K A, Harris J G, Nagamoto H T, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry, 2004, 161(10): 1822-1828.
8. 2009, 29(2): 181-184.
9. 2004, 18(1): 45-47.
10. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatrry, 2008, 64(5): 376-384.
11. 2005, 85(49): 3457-3459.
12. Sanchez-Morla E M, Santos J L, Aparicio A, Garcfa-Jimenez M A, Villanueva C, Martfnez-Vizcafno V, et al. Antipsychotic effects on auditory sensory gating in schizophrenia patients. Eur Neuro-psychopharmacol, 2009, 19(12): 905-905.
13. Adier L E, Cawthra E M, Donovan K A, Harris J G, Nagamoto H T, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry, 2005, 162(2): 386-388.
14. Yee C M, Nuechterlein K H, Morris S E, White P M. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol, 1998, 107(4): 691-698.
15. Arango C, Summerfelt A, Buchanan R W. Olanzapine effects on auditory sensory gating in schizophrenia. Am J Psychiatry, 2003, 160(11): 2066-2068.
16. Becker J, Gomes I, Ghisolfi E S, Schuch A, Ramos F L, Ehlers J A, et al. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol, 2004, 115(2): 396-401.
17. Daskalakis Z J, Christensen B K, Fitzgerald P B, Moller B, Fountain S I, Chen R. Increased cortical inhibition in persons with schizophrenia treated with clozapine. J Psychopharmacol, 2008, 22(2): 203-209.
18. Potter D, Summerfelt A, Gold J, Buchanan R W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull, 2006, 32(4): 692-700.
19. Nagamoto H T, Adier L E, Hea R A, Griffith J M, McRae K A, Freedman R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry, 1996, 40(3): 181-188.
20. Nagamoto H T, Adier L E, McRae K A, HuettI P, Cawthra E, Gerhardt G, et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology, 1999, 39(1): 10-17.